top of page




To maximize the potential for Etna Biotech’s technologies and to enhance the prospects of its R&D pipeline, the company has established a strong network of partnerships. Current R&D collaborations include partnerships with:


  • Istituto Superiore di Sanita, Italy;

  • National Institute of Allergy and Infectiouse Diseases – NIH, US;

  • Infectious Disease Research Institute, US;

  • Instituto de Biologia Molecular e Cellular (IBMC), Portugal;

  • Centro de Biología Molecular "Severo Ochoa", Universidad Autónoma de Madrid, Spain;

  • Swiss Tropical and Public Health Institute, Switzerland;

  • Meditox Sro, Czech Republic;

  • European Vaccine Initiative, Germany;

  • Biomedical Primate Research Centre (BPRC), The Netherlands

  • Central Veterinary Institute, The Netherlands;

  • Instituto de Biologia Experimental e Tecnológica (iBET), Portugal;

  • National Institute for Biological Standards and Control (NIBSC), a centre of the Medicine and Healthcare Products Regulatory Agency (MHRA), United Kingdom;

  • Redbiotec AG (RBT), Switzerland;

  • University of Wien, Austria;

  • University of Catania, Italy;

  • Softeco Sismat SpA, Italy;

  • National Council of the Research, Italy;

  • Scientific and Techonology Park of the Sicily, Italy;

  • Agroindustry Advanced Technologies S.p.A., Italy;

  • Johns Hopkins University, US;

  • The University of Sheffield, United Kingdom;

  • Archivel Farma, Spain;

  • Stichting Tuberculosis Vaccine Initiative (TBVI), The Netherlands;

  • The All India Institute of Medical Sciences (AIIMS), India.

  • University of Bologna, Italy.

bottom of page